The Authority required (Streamlined) listing of denosumab for osteoporosis in women aged ≥ 70 years has changed from 1 August 2012. The required bone mineral density T-score has been changed from ≤ –3.0 to ≤ –2.5. The T-score cut-off is now the same as applies to alendronate for osteoporosis. ¹

The Pharmaceutical Benefits Advisory Committee recommended the change in listing on the basis that, in this patient group, denosumab 60 mg once every 6 months has a similar effect to that of alendronate 70 mg once weekly, at a similar cost.¹ Previously denosumab was listed on the basis of a comparison with zoledronic acid.²

For more information about the place of denosumab in treating postmenopausal osteoporosis see the NPS RADAR review Denosumab (Prolia) for postmenopausal osteoporosis.

For more information about the place of denosumab in treating postmenopausal osteoporosis see the NPS RADAR review Denosumab (Prolia) for postmenopausal osteoporosis.